GC-78-HCl 

GC-78-HCl is an orally and nonpeptidic SARS-CoV-2 M^pro inhibitor, with an IC₅₀ of 0.19 μM for enzyme. GC-78-HCl has excellent antiviral activity and favorable pharmacokinetic properties^[1].

EC₅₀ Tatget: SARS-CoV^[1] EC₅₀: 0.40 μM (SARS-CoV-2), 0.21 ± 0.030 μM (wild-type), 0.21 ± 0.080 μM (Alpha), 0.24 ± 0.080 μM (Delta), 0.25 ± 0.060 μM (Omicron B.1)^[1]

GC-78-HCl (0.01-10 μM) has low cytotoxicity in Vero E6 cells^[1].
GC-78-HCl exhibits potent antiviral activity against SARS-CoV-2 variants and other human coronaviruses in MRC-5/Vero E6 cells, indicates its potential broad-spectrum anticoronaviral activity^[1].
GC-78-HCl (50 μM) has no inhibitory activity against human cathepsins B/F/K/L and Caspase 3, indicates high target specificity toward coronavirus proteases^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

GC-78-HCl (800 mg/kg, p.o., single dosage) has no acute toxicity in Kunming mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

551.85

C₂₅H₂₅Cl₃N₄O₄

3022242-53-8

O=C([C@@H]1CN(CCN1C2=CC(Cl)=C(Cl)C=C2)C(C3=CN=CC=C3OC)=O)NC4=CC=C(C=C4)OC.Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gao S, et al. Design, Synthesis, and Biological Evaluation of Trisubstituted Piperazine Derivatives as Noncovalent Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease Inhibitors with Improved Antiviral Activity and Favorable Druggability. J Med Chem. 2023 Nov 22.  [Content Brief]